Zacks Investment Research Comments on DURECT Co.’s Q1 2019 Earnings (DRRX)
DURECT Co. (NASDAQ:DRRX) – Equities research analysts at Zacks Investment Research issued their Q1 2019 earnings per share estimates for shares of DURECT in a research report issued on Wednesday, March 13th. Zacks Investment Research analyst B. Marckx anticipates that the specialty pharmaceutical company will earn ($0.05) per share for the quarter. Zacks Investment Research also issued estimates for DURECT’s Q2 2019 earnings at ($0.05) EPS and Q4 2019 earnings at ($0.05) EPS.
DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). DURECT had a negative net margin of 136.40% and a negative return on equity of 96.70%. The company had revenue of $3.63 million during the quarter, compared to the consensus estimate of $3.65 million.
Shares of DRRX opened at $0.78 on Friday. DURECT has a one year low of $0.46 and a one year high of $2.55. The stock has a market capitalization of $132.89 million, a PE ratio of -4.88 and a beta of 2.16. The company has a quick ratio of 2.53, a current ratio of 5.45 and a debt-to-equity ratio of 1.03.
Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of DURECT in the 4th quarter valued at about $32,000. Prudential Financial Inc. boosted its holdings in shares of DURECT by 541.8% during the 4th quarter. Prudential Financial Inc. now owns 89,460 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 75,520 shares during the period. SG Americas Securities LLC boosted its holdings in shares of DURECT by 787.0% during the 4th quarter. SG Americas Securities LLC now owns 140,745 shares of the specialty pharmaceutical company’s stock worth $68,000 after buying an additional 124,878 shares during the period. Rhumbline Advisers boosted its holdings in shares of DURECT by 44.6% during the 4th quarter. Rhumbline Advisers now owns 204,285 shares of the specialty pharmaceutical company’s stock worth $99,000 after buying an additional 62,985 shares during the period. Finally, Raymond James & Associates bought a new stake in shares of DURECT during the 4th quarter worth about $171,000. 45.90% of the stock is owned by institutional investors.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.